MetaCap

Climb Bio Inc. (CLYM)

NASDAQ: CLYMHealth CareBiotechnology: Pharmaceutical PreparationsUSD

9.19-0.09 (-0.97%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

CLYM stock chart

Technical analysis

Key statistics

All statistics
Market cap
$539.80M
EPS (TTM)
-$0.81
52-week range
1.64 – 18.33
Day range
8.90 – 9.40
Volume / Avg
770.17K / 1.38M
Beta
—

52-week range

$1.64$18.33

CLYM stock today

On Nov 20, CLYM ended the session at $9.19, shedding $0.09 (0.97%), versus the S&P 500's 3.70% decline. Shares are 49.9% below their 52-week high of $18.33, set on Aug 25, 2026 and 462.1% above the 52-week low of $1.64, in the middle of the past year's range. CLYM is up 129.8% year to date, outperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has gained 440.6%.

Climb Bio has posted a net loss over the last twelve months (EPS of -$0.81), so its P/E ratio is not meaningful.

Summary generated from market data by MetaCap's automated system. Methodology

About Climb Bio

Company profile

Climb Bio, Inc., a clinical-stage biotechnology company, focuses on developing therapies to address unmet needs for patients living with immune-mediated diseases. The company's lead product candidate is the budoprutug, an anti-CD19 monoclonal antibody for the treatment of B-cell mediated diseases. It is also developing budoprutug which is in phase 2 clinical trials for the treatment of primary membranous nephropathy and immune thrombocytopenia; and Phase 1b clinical trial indicated for the systemic lupus erythematosus.

Industry
Biotechnology: Pharmaceutical Preparations
CEO
Dr. Aoife M. Brennan BAO, BCh, M.D., MB, MMSc
Headquarters
Wellesley Hills, MA
Employees
28
IPO year
2021

Financial highlights

Full financials

Climb Bio reported a net loss of $59.9 million, compared with a loss of $73.9 million a year earlier. Diluted earnings per share came in at -$0.88.

Climb Bio annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023FY 2022FY 2021
Revenue—————
Growth—————
Net income$-59.85M$-73.90M$-35.12M$-45.24M$-47.48M
EPS (diluted)$-0.88$-1.53$-1.30$-1.72$-4.24

Analyst forecast

Forecast

Consensus (16 analysts)

strong_buy

Avg. price target

$28.40+209.03%

  • Strong buy 2
  • Buy 14
  • Hold 0
  • Sell 0
  • Strong sell 0

Target range

Low $18.00High $40.00

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Nov 5, 2026
EPS actual vs est.
$-0.18 vs $-0.20
Surprise
+10.00%

CLYM news

All CLYM news

Climb Bio peers

Health Care sector
CLYM peer companies
CompanyPrice% ChgMarket capCompare
ACRSAclaris Therapeutics Inc.3.44-1.71%$545.63Mvs CLYM
AVBPArriVent BioPharma Inc.10.52-6.57%$544.13Mvs CLYM
CBIOCrescent Biopharma Inc.13.00+0.70%$543.21Mvs CLYM
ANLAdlai Nortye Group Ltd. ADR8.55-5.63%$550.60Mvs CLYM
BCAXBicara Therapeutics Inc.8.44-7.46%$560.31Mvs CLYM
GERNGeron Corporation0.8707-4.63%$560.94Mvs CLYM
ZVRAZevra Therapeutics Inc.8.76-3.42%$521.26Mvs CLYM
ALMSAlumis Inc.3.96-8.54%$514.09Mvs CLYM

Indexes, lists and sector

Climb Bio stock FAQ

What is Climb Bio's stock price today?

CLYM last traded at $9.19 as of Nov 20, 4:00 PM EST, down 0.97% on the day. Prices are delayed at least 15 minutes.

Who is Climb Bio's CEO?

Dr. Aoife M. Brennan BAO, BCh, M.D., MB, MMSc is the chief executive officer of Climb Bio Inc., which has about 28 employees.

What is the CLYM 52-week high?

The 52-week high for CLYM is $18.33 and the 52-week low is $1.64. The stock is currently 49.9% below its high.

Compare CLYM